The FDA’s new timeline
In a filing submitted on Wednesday night to a federal court in Louisiana, the FDA said it expects to receive the results of a study on mifepristone’s safety risks in December, after which it will analyse them and publish a report, completing the full review by March 2027.
According to the FDA, the safety review involves comparing a sample of 100,000 women who used mifepristone with a control group who had surgical abortions. The agency is conducting statistical analysis to detect any safety risks that may not yet have been identified.
Changes that could follow
The review’s findings could lead to several regulatory changes for the drug:
- Repealing the 2023 rule allowing remote prescribing and dispensing by mail
- Reinstating the in-person dispensing requirement, as some petitions to the FDA propose
- Reconsidering mifepristone’s original 2000 approval, though that would be a difficult and lengthy process
The FDA said it is also evaluating several petitions urging it to take various measures.















